China
Wall Street Banks Court Sovereign Funds for Syngenta’s $9 Billion IPO
Wall Street banks are helping approach international investors for Syngenta Group's 65 billion yuan ($9 billion) initial public offering in Shanghai.
Novartis terminates its option agreement with BeiGene
BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Termination Agreement”) to mutually terminate the Option Agreement, effective immediately.
Chinese biopharmaceutical firm Pyrotech Therapeutics bags $97m in Series A round
Chinese biopharmaceutical firm Pyrotech Therapeutics has secured 700 million yuan ($97.2 million) in a Series A financing round co-led by state-owned investment firms SDIC Venture Capital and China Venture Capital, according to a company release on Monday
InnoCare and ArriVent Announce Clinical Development Collaboration
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases and ArriVent Biopharma, a clinical stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced a clinical development collaboration.
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology announces that, it is anticipated that the Company will record a significant increase in its revenue for the six months ended June 30, 2023.
HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced a clinical supply agreement with AstraZeneca in China.
Astellas Completes Acquisition of Iveric Bio
stellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition").
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in Molecular Metabolism.
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) in combination with obinutuzumabfor the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after at least two prior lines of therapy.
